Skip to main content

2seventy bio, Inc. (TSVT)

NASDAQ: TSVT · IEX Real-Time Price · USD
27.13 -1.30 (-4.57%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap662.06M
Revenue (ttm)248.95M
Net Income (ttm)-108.04M
Shares Out24.40M
EPS (ttm)-4.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume491,380
Open28.27
Previous Close28.43
Day's Range26.06 - 28.27
52-Week Range13.77 - 64.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently...

IndustryDrug Manufacturers-General
IPO DateNov 5, 2021
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolTSVT
Full Company Profile

Financial Performance

In 2020, 2seventy bio's revenue was $248.12 million, an increase of 460.15% compared to the previous year's $44.30 million. Losses were -$120.11 million, -62.53% less than in 2019.

Financial Statements

News

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30...

3 days ago - Business Wire

2seventy bio to Present at the 5th Annual Cowen IO Next Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the 5th Annual Cowen IO Next Summit on November 15, at 1:15pm ET. A we...

3 weeks ago - Business Wire

2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd American Society of Hematology...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT) announced today that data from its pipeline of oncology cell therapies will be presented, including two oral presentations, at the 63...

1 month ago - Business Wire

2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc., (NASDAQ: TSVT), an emerging immuno-oncology company today announced its official launch as an independent, publicly traded company. 2seventy bio wi...

1 month ago - Business Wire